Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 23612012)

1.

Targeting the BRAF V600E mutation in multiple myeloma.

Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS.

Cancer Discov. 2013 Aug;3(8):862-9. doi: 10.1158/2159-8290.CD-13-0014. Epub 2013 Apr 23.

2.

Targeting BRAF in multiple myeloma.

O'Donnell E, Raje NS.

Cancer Discov. 2013 Aug;3(8):840-2. doi: 10.1158/2159-8290.CD-13-0297.

3.

BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.

Bohn OL, Hsu K, Hyman DM, Pignataro DS, Giralt S, Teruya-Feldstein J.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):e65-8. doi: 10.1016/j.clml.2013.12.003. Epub 2013 Dec 17. No abstract available.

PMID:
24445188
4.

Molecular platforms utilized to detect BRAF V600E mutation in melanoma.

Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG.

Semin Cutan Med Surg. 2012 Dec;31(4):267-73. doi: 10.1016/j.sder.2012.07.007.

PMID:
23174497
5.

Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.

Kaplan HG.

J Natl Compr Canc Netw. 2013 Dec 1;11(12):1466-70.

PMID:
24335681
6.

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ, Stafl J, Miller VA, Ali SM.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. doi: 10.1016/j.clml.2014.06.004. Epub 2014 Jun 11. No abstract available.

PMID:
24997557
7.

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R.

J Transl Med. 2010 Jul 14;8:67. doi: 10.1186/1479-5876-8-67.

8.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
9.

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA.

J Clin Invest. 2011 Dec;121(12):4700-11. doi: 10.1172/JCI46382. Epub 2011 Nov 21.

10.

Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.

Follows GA, Sims H, Bloxham DM, Zenz T, Hopper MA, Liu H, Bench A, Wright P, Van't Veer MB, Scott MA.

Br J Haematol. 2013 Apr;161(1):150-3. doi: 10.1111/bjh.12201. Epub 2012 Dec 29. No abstract available.

PMID:
23278307
11.

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS.

Cancer Discov. 2012 May;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1.

12.

Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.

Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J.

Lung Cancer. 2013 Nov;82(2):365-7. doi: 10.1016/j.lungcan.2013.08.012. Epub 2013 Aug 19.

PMID:
24035431
13.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

14.

The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.

Ponti G, Pellacani G, Tomasi A, Gelsomino F, Spallanzani A, Depenni R, Al Jalbout S, Simi L, Garagnani L, Borsari S, Conti A, Ruini C, Fontana A, Luppi G.

J Clin Pathol. 2013 May;66(5):441-5. doi: 10.1136/jclinpath-2012-201345. Epub 2013 Mar 5.

PMID:
23463675
15.

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.

Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J.

Int J Cancer. 2011 May 1;128(9):2075-84. doi: 10.1002/ijc.25555.

PMID:
20635392
16.

Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.

Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G.

Haematologica. 2013 Feb;98(2):e20-2. doi: 10.3324/haematol.2012.082404. Epub 2013 Jan 8. No abstract available.

17.

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.

Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G.

Cancer Res. 2012 Feb 15;72(4):969-78. doi: 10.1158/0008-5472.CAN-11-1875. Epub 2011 Dec 28.

18.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R.

Nature. 2012 Jan 26;483(7387):100-3. doi: 10.1038/nature10868.

PMID:
22281684
19.

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.

Charles J, Beani JC, Fiandrino G, Busser B.

J Am Acad Dermatol. 2014 Sep;71(3):e97-9. doi: 10.1016/j.jaad.2014.03.038. No abstract available.

20.

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.

Robinson GW, Orr BA, Gajjar A.

BMC Cancer. 2014 Apr 12;14:258. doi: 10.1186/1471-2407-14-258.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk